Karyopharm jumps as blood cancer drug meets one of two main goals in study

Karyopharm Therapeutics

24/03/2026 12:14

Updates

** Shares of drugmaker Karyopharm Therapeutics KPTI.O rise 22% to $8.15 premarket

** Co says its selinexor-plus-ruxolitinib combo met one of two main goals in a late-stage trial in myelofibrosis, a rare blood cancer that causes bone marrow scarring and an enlarged spleen

** Selinexor is already approved under the brand name Xpovio for other blood cancers, including multiple myeloma and lymphoma, but not for myelofibrosis

** Trial compared Xpovio plus Incyte’s INCY.O Jakafi with Jakafi alone, with 50% of combo patients achieving meaningful spleen shrinkage versus 28% on Jakafi

** Trial met the spleen size reduction goal but did not show a clear difference on symptom improvement versus ruxolitinib alone, co says

** Co also flagged a possible survival benefit signal and said it plans to meet the FDA to discuss next steps

** Separately, Karyopharm agreed to a $30 million private placement with RA Capital, with up to $44 million more if accompanying warrants are fully exercised

** Shares fell ~27% in 2025

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))